CGN Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Diversified Revenue Growth Across Healthcare And Pharmacy ServicesGrowth across both Cigna Healthcare and Evernorth demonstrates broad demand for the company’s insurance, pharmacy, and specialty-care platforms. Diversification across these services can support durable expansion, reduce reliance on one earnings stream, and strengthen the company’s ability to reinvest in scale and capabilities.
Strong And Durable Cash GenerationSubstantial operating cash flow gives Cigna financial capacity to fund technology investments, support operations, reduce leverage, and return capital to shareholders. The multi-year cash-flow target also indicates management expects the business model to remain highly cash generative beyond the current reporting period.
High Client Retention And Technology-enabled Care AdvantagesVery high PBM retention indicates meaningful customer stickiness and supports recurring fee revenue, while AI-enabled clinical tools can improve service efficiency and outcomes. Together, retention, data, and measurable care savings may reinforce Cigna’s competitive position over several quarters.
Bears Say
Margin Compression And Earnings VariabilityThe company’s revenue growth has not translated into consistently expanding profitability, showing that cost and mix pressures remain material. Thin, volatile margins leave less protection against adverse utilization or pricing changes and can make earnings less predictable over the next several quarters.
Persistently Elevated Medical Cost Trends Threaten Insurance MarginsSustained high medical-cost inflation can pressure the spread between premiums and claims, particularly if pricing or benefit adjustments lag utilization. The expected seasonal MCR increase highlights an ongoing margin risk that could constrain Cigna Healthcare earnings even as membership grows.
PBM Earnings Pressure From Transition Investment And Changing EconomicsThe move toward the rebate-free Signature model requires sizable transition spending and has already reduced PBS earnings. Continued investment through 2027 creates a durable near-term drag, while changing drug economics may pressure PBM margins before expected operational benefits materialize.
CGN FAQ
What was Cigna Corp’s price range in the past 12 months?
Currently, no data Available
What is Cigna Corp’s market cap?
Cigna Corp’s market cap is CHF62.39B.
When is Cigna Corp’s upcoming earnings report date?
Cigna Corp’s upcoming earnings report date is Nov 05, 2026 which is in 23 days.
How were Cigna Corp’s earnings last quarter?
Cigna Corp released its earnings results on Jul 30, 2026. The company reported CHF6.483 earnings per share for the quarter, beating the consensus estimate of CHF6.33 by CHF0.153.
Is Cigna Corp overvalued?
According to Wall Street analysts Cigna Corp’s price is currently Undervalued.
Does Cigna Corp pay dividends?
Cigna Corp does not currently pay dividends.
What is Cigna Corp’s EPS estimate?
Cigna Corp’s EPS estimate is 6.27.
How many shares outstanding does Cigna Corp have?
Cigna Corp has 264,240,480 shares outstanding.
What happened to Cigna Corp’s price movement after its last earnings report?
Cigna Corp reported an EPS of CHF6.483 in its last earnings report, beating expectations of CHF6.33. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Cigna Corp?
Currently, no hedge funds are holding shares in CH:CGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cigna Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF282.01 (― Upside)
CHF282.01 (― Upside)
Blogger Sentiment
Bullish
CH:CGN Sentiment 67%
Sector Average 66%
Sector Average 66%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-3.64%
12-Months-Change
Fundamentals
Return on Equity
15.24%
Trailing 12-Months
Asset Growth
3.90%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cigna Corp
Cigna Group, established in 1792 and headquartered in Bloomfield, Connecticut, provides insurance products and related services across the United States. The company operates through two primary segments. Its Evernorth division offers a comprehensive array of coordinated and specialized health solutions, including pharmacy services, benefits administration, care management and delivery, and advanced intelligence solutions. These offerings cater to a diverse clientele, such as health plans, employers, government entities, and healthcare providers. Meanwhile, the Cigna Healthcare segment delivers an extensive portfolio of products and services, encompassing medical, pharmaceutical, behavioral health, dental, vision, and health advocacy programs for both insured and self-insured customers. This segment also provides Medicare Advantage, Medicare Supplement, and Medicare Part D plans specifically for seniors, in addition to individual health insurance options available on and off public exchanges. Globally, Cigna Healthcare extends international health coverage and benefits to mobile professionals and employees of multinational organizations. Furthermore, the company issues permanent insurance contracts to corporations, designed to cover the lives of specific employees for funding future benefit obligations. Cigna distributes its various offerings through insurance brokers and consultants, direct sales channels to employers, unions, and individuals, and via both private and public exchanges.
CGN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational and financial momentum driven by specialty drug growth, Evernorth and Cigna Healthcare outperformance, AI-enabled clinical initiatives with measurable outcomes, solid revenue and EPS beats, and an upgraded full-year EPS outlook. Offsetting items include PBS earnings pressure from transition investments and economic shifts due to biosimilars, moderating GLP-1 utilization, persistently elevated medical cost trends, IDR-related affordability concerns, and one-time special charges. Overall, the positive drivers (revenue growth, margin gains in Specialty, upgraded guidance, retention/new-business strength, AI initiatives) materially outweigh the manageable challenges described.View all CH:CGN earnings summaries







